Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/1998

01-08-1998 | ORIGINAL ARTICLE

Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells

Authors: Kun Li, Medi Adibzadeh, Thomas Halder, Hubert Kalbacher, Susanne Heinzel, Claudia Müller, Jesper Zeuthen, Graham Pawelec

Published in: Cancer Immunology, Immunotherapy | Issue 1/1998

Login to get access
Metadata
Title
Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
Authors
Kun Li
Medi Adibzadeh
Thomas Halder
Hubert Kalbacher
Susanne Heinzel
Claudia Müller
Jesper Zeuthen
Graham Pawelec
Publication date
01-08-1998
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/1998
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050501

Other articles of this Issue 1/1998

Cancer Immunology, Immunotherapy 1/1998 Go to the issue

ORIGINAL ARTICLE

Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells

ORIGINAL ARTICLE

Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01

ORIGINAL ARTICLE

Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma

ORIGINAL ARTICLE

Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres

REVIEW

Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer

ORIGINAL ARTICLE

Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits